文献速递浆细胞疾病

达雷妥尤单抗治疗经治系统性轻链淀粉样变性的前瞻性2期试验

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
PubMed 文献 · Blood · 2020-01-01

这项多中心前瞻性2期研究评估达雷妥尤单抗单药治疗40例经治AL淀粉样变性患者,dFLC>50 mg/L,中位年龄69岁,26例≥2器官受累。19例(47.5%)达VGPR及以上,中位血液学缓解时间1周,2年OS率74%(95%CI 62-81),安全性良好。

要点

  • 达雷妥尤单抗单药在经治AL淀粉样变性中深度快速血液学缓解,47.5%达VGPR及以上。
  • 中位血液学缓解时间仅1周,4剂后无缓解者继续应答可能性低。
  • 2年OS率74%(95%CI 62-81),安全性与已知一致,无意外不良事件。

核心结论

  • 达雷妥尤单抗单药在经治AL淀粉样变性患者中可诱导深度且快速的血液学缓解,安全性良好。

研究设计与样本

  • 前瞻性多中心2期研究(NCT02816476),纳入40例经治AL淀粉样变性且dFLC>50 mg/L患者,来自15个中心,2016年9月至2018年4月入组。
  • 患者接受6个28天周期静脉达雷妥尤单抗,第1-2周期每周一次,第3-6周期每2周一次。
  • 中位年龄69岁(范围45-83),26例≥2个器官受累,心脏受累24例、肾脏受累26例。
  • 自诊断至入组中位时间23个月(四分位距4-122),中位既往治疗线数3(范围1-5)。

主要发现

  • 22例获血液学缓解,19例(47.5%)达VGPR及以上(dFLC<40 mg/L)。
  • 中位血液学缓解时间1周,4剂后无缓解者进一步应答可能性低。
  • 肾脏缓解8例,心脏缓解7例。
  • 中位随访26个月,2年总生存率74%(95%CI 62-81)。
  • 达雷妥尤单抗耐受性良好,无意外不良事件。

临床怎么用

  • 达雷妥尤单抗单药可作为经治AL淀粉样变性的治疗选择,尤其适合需快速深度缓解者。
  • 治疗4剂后未达血液学缓解者,继续单药应答可能性低,宜考虑调整方案。

局限性

  • 单臂2期研究,无对照组,样本量40例。
  • 所有患者既往接受过治疗,中位既往治疗3线,结论外推至初治患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report the results of a prospective multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476). Forty previously treated AL patients with a difference between involved and uninvolved free light chains (dFLC) >50 mg/L were included in 15 centers between September of 2016 and April of 2018. Patients received 6 28-day cycles of IV daratumumab, every week for cycles 1 and 2 and every 2 weeks for cycles 3 through 6. Median age was 69 years (range, 45-83). Twenty-six patients had ≥2 organs involved, with heart in 24 and kidney in 26. Median time from diagnosis to enrollment was 23 months (interquartile range, 4-122), with a median of 3 prior therapies (range, 1-5). At data cutoff (September of 2019), all patients discontinued therapy; 33 received the planned 6 cycles. Overall, 22 patients had hematological response, and 19 patients (47.5%) achieved very good partial response (dFLC <40 mg/L) or better. Median time to hematological response was 1 week. Patients with no response after 4 doses were unlikely to respond further. Renal and cardiac responses occurred in 8 and 7 patients, respectively. Daratumumab was well tolerated, with no unexpected adverse events. With a median follow-up of 26 months, the 2-year overall survival rate was 74% (95% confidence interval, 62-81). Daratumumab monotherapy is associated with deep and rapid hematological responses in previously treated AL patients, with a good safety profile. Further studies of daratumumab in combination regimens are warranted.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020. PMID: 32108228. doi:10.1182/blood.2019004369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。